Our Services
Medical Information
Helpful Resources
Published on: 9/28/2026
Topiramate (Topamax) commonly causes tingling or "pins and needles" in the hands, feet, and face, word-finding difficulty or mental fogginess, and an increased risk of kidney stones, though severity varies widely by dose and individual. Less common but serious effects include vision changes, decreased sweating with overheating, metabolic acidosis, and mood shifts, and several of these warrant prompt medical attention rather than watchful waiting. Timing matters too, since some effects fade as the body adjusts while others signal a need to change the dose or the drug entirely. There are important distinctions between expected, manageable reactions and warning signs, so see below to understand more.
If your symptoms are hard to place, a free, instant, online symptom check can help you organize what you are feeling, flag patterns that deserve urgent review, and prepare clearer questions for your prescriber before your next appointment.
Last reviewed for medical accuracy: 09/28/2026
Topamax (generic name: topiramate) is a medication commonly prescribed for seizure control and migraine prevention. Like any drug, it can cause side effects. This guide focuses on three notable issues—tingling, word-finding trouble, and kidney stones—while also outlining other possible reactions and when to seek medical help.
Topamax works by stabilizing electrical activity in the brain. It can be very effective, but it’s important to know the potential side effects and how to manage them.
Most side effects are mild to moderate and may improve over time. Common reactions include:
Below, we explore in detail the symptoms of tingling, word-finding trouble, and kidney stones, with tips for managing each.
Topamax can interfere with certain nerve signals, leading to temporary nerve irritation. This effect is often dose-related.
Up to 30% of patients report some degree of paresthesia, especially at higher doses.
If tingling is severe, affects daily tasks, or continues beyond two months, discuss alternatives with your healthcare provider.
Topamax can influence neurotransmitter levels and slow certain brain processes. These cognitive effects tend to be dose-dependent.
Approximately 15–20% of users report mild word-finding issues. More severe cognitive changes are less common.
If cognitive issues interfere with work, school, or safety, reach out to your healthcare professional for a possible dose review.
Topamax can increase urine pH and calcium excretion, creating an environment where stones form more easily.
Studies suggest kidney stones occur in 1–2% of Topamax users, higher than in the general population.
If you suspect a kidney stone, seek medical attention promptly to manage pain and prevent complications.
While less common, be aware of these potential issues:
Some side effects can be serious or life-threatening. Contact your doctor or go to the emergency department if you experience:
For anything that feels life-threatening or severe, never hesitate to call emergency services or get to a hospital.
If you’re experiencing new or troubling symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you understand possible causes and decide when to seek medical care.
Always discuss any side effects or concerns with your prescribing doctor, especially before adjusting or stopping Topamax.
Topamax can be a highly effective treatment for seizures and migraines, but it comes with potential side effects like tingling, word-finding trouble, and kidney stones. Most reactions are manageable, especially with the right strategies and medical support. Always keep the lines of communication open with your healthcare provider. If you ever feel that a side effect is severe or life-threatening, seek medical help right away.
Speak to a doctor about any serious or persistent symptoms to ensure your treatment is both safe and effective.
(References)
* Sander JW. Practical aspects of the use of topiramate in patients with epilepsy. Epilepsia. 1997;38 Suppl 1:S56-8. doi: 10.1111/j.1528-1157.1997.tb04521.x. PMID: 9092962.
* Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med. 2004;55:505-18. doi: 10.1146/annurev.med.55.091902.104440. PMID: 14746533.
* Bootsma HP, Ricker L, Hekster YA, Hulsman J, Lambrechts D, Majoie M, Schellekens A, de Krom M, Aldenkamp AP. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009 Jun;18(5):327-31. doi: 10.1016/j.seizure.2008.11.006. Epub 2008 Dec 24. PMID: 19110447.
* Saffra N, Smith SN, Seidman CJ. Topiramate-induced refractive change and angle closure glaucoma and its ultrasound bimicroscopy findings. BMJ Case Rep. 2012 Aug 1;2012. doi: 10.1136/bcr-2012-006509. Epub 2012 Aug 1. PMID: 22859383; PMCID: PMC4543431.
* Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother. 2015 Jun;16(8):1263-74. doi: 10.1517/14656566.2015.1041505. PMID: 25958964.
* Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, Semlitsch T. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4. Epub 2016 Mar 2. PMID: 26934640.
* Miyake S, Sugita M, Okazaki T, Takenaka M, Kuwabara K, Ogawa K. Microseizures Induced by Topiramate. Acta Med Okayama. 2018 Aug;72(4):419-422. doi: 10.18926/AMO/56181. PMID: 30140091.
* Lupianez-Merly C, Dilmaghani S, Vosoughi K, Camilleri M. Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks. Aliment Pharmacol Ther. 2024 Feb;59(4):475-491. doi: 10.1111/apt.17856. Epub 2024 Jan 2. PMID: 38169126.
* Canales BK, Heiman J, Terry R, Bird VG, DiBianco J, Marks J, Canales MT. Phentermine/Topiramate in Obese, Diabetic Uric Acid Stone Formers: An Open-Label Randomized Feasibility Trial. J Urol. 2026 Oct;216(4):500-510. doi: 10.1097/JU.0000000000005189. Epub 2026 Jun 26. PMID: 42361212.
* Stogios N, Agarwal SM, Maksyutynska K, Faisal H, Pless LL, Pillinger T, Humber B, Taylor VH, Remington G, Faulkner GEJ, Hahn MK. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2026 Sep 1;83(9):912-920. doi: 10.1001/jamapsychiatry.2026.1814. PMID: 42418179; PMCID: PMC13347271.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.